|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ATG7 |
Gene summary for ATG7 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ATG7 | Gene ID | 10533 |
| Gene name | autophagy related 7 | |
| Gene Alias | APG7-LIKE | |
| Cytomap | 3p25.3 | |
| Gene Type | protein-coding | GO ID | GO:0000045 | UniProtAcc | O95352 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10533 | ATG7 | CCI_1 | Human | Cervix | CC | 1.41e-05 | 7.90e-01 | 0.528 |
| 10533 | ATG7 | CCI_2 | Human | Cervix | CC | 1.80e-07 | 7.04e-01 | 0.5249 |
| 10533 | ATG7 | CCI_3 | Human | Cervix | CC | 1.43e-17 | 9.27e-01 | 0.516 |
| 10533 | ATG7 | CCII_1 | Human | Cervix | CC | 9.01e-03 | 2.36e-01 | 0.3249 |
| 10533 | ATG7 | HTA11_347_2000001011 | Human | Colorectum | AD | 1.43e-12 | 7.54e-01 | -0.1954 |
| 10533 | ATG7 | HTA11_1391_2000001011 | Human | Colorectum | AD | 4.73e-03 | 5.22e-01 | -0.059 |
| 10533 | ATG7 | A001-C-207 | Human | Colorectum | FAP | 4.06e-02 | -1.90e-01 | 0.1278 |
| 10533 | ATG7 | A015-C-203 | Human | Colorectum | FAP | 2.10e-31 | -5.47e-01 | -0.1294 |
| 10533 | ATG7 | A015-C-204 | Human | Colorectum | FAP | 3.87e-06 | -3.35e-01 | -0.0228 |
| 10533 | ATG7 | A014-C-040 | Human | Colorectum | FAP | 1.45e-04 | -4.51e-01 | -0.1184 |
| 10533 | ATG7 | A002-C-201 | Human | Colorectum | FAP | 2.08e-14 | -4.10e-01 | 0.0324 |
| 10533 | ATG7 | A002-C-203 | Human | Colorectum | FAP | 2.96e-03 | -9.38e-02 | 0.2786 |
| 10533 | ATG7 | A001-C-119 | Human | Colorectum | FAP | 3.80e-08 | -4.93e-01 | -0.1557 |
| 10533 | ATG7 | A001-C-108 | Human | Colorectum | FAP | 1.39e-18 | -4.09e-01 | -0.0272 |
| 10533 | ATG7 | A002-C-205 | Human | Colorectum | FAP | 4.24e-24 | -4.99e-01 | -0.1236 |
| 10533 | ATG7 | A001-C-104 | Human | Colorectum | FAP | 7.71e-04 | -2.89e-01 | 0.0184 |
| 10533 | ATG7 | A015-C-005 | Human | Colorectum | FAP | 1.34e-05 | -3.13e-01 | -0.0336 |
| 10533 | ATG7 | A015-C-006 | Human | Colorectum | FAP | 7.43e-22 | -5.81e-01 | -0.0994 |
| 10533 | ATG7 | A015-C-106 | Human | Colorectum | FAP | 1.13e-08 | -2.83e-01 | -0.0511 |
| 10533 | ATG7 | A002-C-114 | Human | Colorectum | FAP | 1.89e-25 | -6.04e-01 | -0.1561 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001603210 | Cervix | CC | viral process | 109/2311 | 415/18723 | 5.40e-15 | 6.46e-12 | 109 |
| GO:004217610 | Cervix | CC | regulation of protein catabolic process | 104/2311 | 391/18723 | 9.39e-15 | 9.36e-12 | 104 |
| GO:004573210 | Cervix | CC | positive regulation of protein catabolic process | 65/2311 | 231/18723 | 7.44e-11 | 1.39e-08 | 65 |
| GO:000697910 | Cervix | CC | response to oxidative stress | 102/2311 | 446/18723 | 2.99e-10 | 4.36e-08 | 102 |
| GO:000989610 | Cervix | CC | positive regulation of catabolic process | 109/2311 | 492/18723 | 5.26e-10 | 6.99e-08 | 109 |
| GO:005170110 | Cervix | CC | biological process involved in interaction with host | 57/2311 | 203/18723 | 1.18e-09 | 1.41e-07 | 57 |
| GO:007149610 | Cervix | CC | cellular response to external stimulus | 78/2311 | 320/18723 | 1.82e-09 | 1.98e-07 | 78 |
| GO:004440310 | Cervix | CC | biological process involved in symbiotic interaction | 71/2311 | 290/18723 | 7.94e-09 | 6.98e-07 | 71 |
| GO:003133110 | Cervix | CC | positive regulation of cellular catabolic process | 91/2311 | 427/18723 | 9.64e-08 | 5.25e-06 | 91 |
| GO:006219710 | Cervix | CC | cellular response to chemical stress | 76/2311 | 337/18723 | 1.01e-07 | 5.25e-06 | 76 |
| GO:003133010 | Cervix | CC | negative regulation of cellular catabolic process | 63/2311 | 262/18723 | 1.10e-07 | 5.68e-06 | 63 |
| GO:00075689 | Cervix | CC | aging | 75/2311 | 339/18723 | 2.75e-07 | 1.13e-05 | 75 |
| GO:00316689 | Cervix | CC | cellular response to extracellular stimulus | 59/2311 | 246/18723 | 3.03e-07 | 1.24e-05 | 59 |
| GO:000989510 | Cervix | CC | negative regulation of catabolic process | 69/2311 | 320/18723 | 2.15e-06 | 6.55e-05 | 69 |
| GO:00485118 | Cervix | CC | rhythmic process | 65/2311 | 298/18723 | 2.79e-06 | 8.04e-05 | 65 |
| GO:003459910 | Cervix | CC | cellular response to oxidative stress | 63/2311 | 288/18723 | 3.58e-06 | 9.50e-05 | 63 |
| GO:003166710 | Cervix | CC | response to nutrient levels | 92/2311 | 474/18723 | 5.80e-06 | 1.42e-04 | 92 |
| GO:00092678 | Cervix | CC | cellular response to starvation | 39/2311 | 156/18723 | 1.04e-05 | 2.32e-04 | 39 |
| GO:00425948 | Cervix | CC | response to starvation | 46/2311 | 197/18723 | 1.24e-05 | 2.59e-04 | 46 |
| GO:00316698 | Cervix | CC | cellular response to nutrient levels | 49/2311 | 215/18723 | 1.32e-05 | 2.68e-04 | 49 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0421614 | Cervix | CC | Ferroptosis | 14/1267 | 41/8465 | 1.75e-03 | 7.21e-03 | 4.26e-03 | 14 |
| hsa0421615 | Cervix | CC | Ferroptosis | 14/1267 | 41/8465 | 1.75e-03 | 7.21e-03 | 4.26e-03 | 14 |
| hsa04216 | Colorectum | AD | Ferroptosis | 21/2092 | 41/8465 | 2.23e-04 | 1.78e-03 | 1.13e-03 | 21 |
| hsa04140 | Colorectum | AD | Autophagy - animal | 49/2092 | 141/8465 | 4.58e-03 | 2.20e-02 | 1.40e-02 | 49 |
| hsa042161 | Colorectum | AD | Ferroptosis | 21/2092 | 41/8465 | 2.23e-04 | 1.78e-03 | 1.13e-03 | 21 |
| hsa041401 | Colorectum | AD | Autophagy - animal | 49/2092 | 141/8465 | 4.58e-03 | 2.20e-02 | 1.40e-02 | 49 |
| hsa042164 | Colorectum | FAP | Ferroptosis | 18/1404 | 41/8465 | 3.49e-05 | 3.65e-04 | 2.22e-04 | 18 |
| hsa042165 | Colorectum | FAP | Ferroptosis | 18/1404 | 41/8465 | 3.49e-05 | 3.65e-04 | 2.22e-04 | 18 |
| hsa042166 | Colorectum | CRC | Ferroptosis | 13/1091 | 41/8465 | 1.36e-03 | 1.08e-02 | 7.33e-03 | 13 |
| hsa042167 | Colorectum | CRC | Ferroptosis | 13/1091 | 41/8465 | 1.36e-03 | 1.08e-02 | 7.33e-03 | 13 |
| hsa041407 | Lung | IAC | Autophagy - animal | 28/1053 | 141/8465 | 7.64e-03 | 3.03e-02 | 2.01e-02 | 28 |
| hsa042169 | Lung | IAC | Ferroptosis | 11/1053 | 41/8465 | 9.62e-03 | 3.68e-02 | 2.44e-02 | 11 |
| hsa0414012 | Lung | IAC | Autophagy - animal | 28/1053 | 141/8465 | 7.64e-03 | 3.03e-02 | 2.01e-02 | 28 |
| hsa0421612 | Lung | IAC | Ferroptosis | 11/1053 | 41/8465 | 9.62e-03 | 3.68e-02 | 2.44e-02 | 11 |
| hsa0421622 | Lung | AIS | Ferroptosis | 11/961 | 41/8465 | 4.84e-03 | 2.45e-02 | 1.57e-02 | 11 |
| hsa0414022 | Lung | AIS | Autophagy - animal | 26/961 | 141/8465 | 8.23e-03 | 3.71e-02 | 2.37e-02 | 26 |
| hsa0421632 | Lung | AIS | Ferroptosis | 11/961 | 41/8465 | 4.84e-03 | 2.45e-02 | 1.57e-02 | 11 |
| hsa0414032 | Lung | AIS | Autophagy - animal | 26/961 | 141/8465 | 8.23e-03 | 3.71e-02 | 2.37e-02 | 26 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ATG7 | SNV | Missense_Mutation | c.589N>T | p.Pro197Ser | p.P197S | O95352 | protein_coding | tolerated(0.12) | benign(0.255) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| ATG7 | SNV | Missense_Mutation | c.2086N>A | p.Asp696Asn | p.D696N | O95352 | protein_coding | deleterious(0.02) | benign(0.03) | TCGA-BH-A0EE-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | SD | |
| ATG7 | SNV | Missense_Mutation | novel | c.469G>A | p.Glu157Lys | p.E157K | O95352 | protein_coding | tolerated(0.16) | benign(0.021) | TCGA-BH-A2L8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
| ATG7 | SNV | Missense_Mutation | c.1900N>C | p.Asp634His | p.D634H | O95352 | protein_coding | tolerated(0.2) | benign(0.01) | TCGA-C8-A275-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| ATG7 | SNV | Missense_Mutation | c.1073N>A | p.Cys358Tyr | p.C358Y | O95352 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ATG7 | SNV | Missense_Mutation | rs371208293 | c.1070N>G | p.Lys357Arg | p.K357R | O95352 | protein_coding | tolerated(0.83) | benign(0.366) | TCGA-E2-A14N-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
| ATG7 | SNV | Missense_Mutation | c.167C>T | p.Ser56Phe | p.S56F | O95352 | protein_coding | tolerated(0.09) | benign(0.169) | TCGA-GM-A2D9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| ATG7 | insertion | In_Frame_Ins | novel | c.1214_1215insAAGAAGACACTCATTTTCCTACCGCTT | p.Asp405delinsGluArgArgHisSerPheSerTyrArgPhe | p.D405delinsERRHSFSYRF | O95352 | protein_coding | TCGA-AN-A0FN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| ATG7 | SNV | Missense_Mutation | novel | c.34A>G | p.Lys12Glu | p.K12E | O95352 | protein_coding | tolerated(0.53) | benign(0.046) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| ATG7 | SNV | Missense_Mutation | novel | c.794T>G | p.Val265Gly | p.V265G | O95352 | protein_coding | deleterious(0) | probably_damaging(0.968) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |